Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor
Twenty-five previously untreated patients with metastatic renal cell carcinoma were treated with 5-day cycles of continuous infusion of interleukin 2 (IL2) and lymphokine-activated killer cell reinfusion. Five achieved a partial response. Three patients were found to have detectable tumor necrosis f...
Gespeichert in:
| Veröffentlicht in: | Cancer research (Chicago, Ill.) Ill.), 1990-04, Vol.50 (8), p.2371-2374 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2374 |
|---|---|
| container_issue | 8 |
| container_start_page | 2371 |
| container_title | Cancer research (Chicago, Ill.) |
| container_volume | 50 |
| creator | BLAY, J.-Y FAVROT, M. C NEGRIER, S COMBARET, V SALEM CHOUAIB MERCATELLO, A KAEMMERLEN, P FRANKS, C. R PHILIP, T |
| description | Twenty-five previously untreated patients with metastatic renal cell carcinoma were treated with 5-day cycles of continuous infusion of interleukin 2 (IL2) and lymphokine-activated killer cell reinfusion. Five achieved a partial response. Three patients were found to have detectable tumor necrosis factor (TNF) in serum before initiation of therapy. On the fifth day of therapy, 24 patients had circulating TNF with immunoradiometric assay whereas 13 had detectable biological activity. Two days after the end of IL2 therapy, TNF concentration (immunoradiometric assay) decreased in most cases but was still detectable in 17 patients. Thirteen patients had still circulating TNF bioactivity. Although there was no significant difference between TNF levels observed on the fifth day of therapy in the responder and nonresponder groups, 48 h after the end of IL2 infusion, both the TNF concentration and the biological activity were significantly higher in the group of responder patients. This result suggests that the clinical response to IL2 therapy in patients with metastatic renal cell carcinoma is correlated to a sustained production of TNF after the end of IL2 infusion. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_79690328</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79690328</sourcerecordid><originalsourceid>FETCH-LOGICAL-h299t-824b862a4fb5055b2a53e8f45b3fa40cb39c88089e137be0989c89824ba61dfe3</originalsourceid><addsrcrecordid>eNqFkUFLxDAQhYMo67r6E4QcxFshTZo2OcqirrDgRc8lSSdstE1qkiL7761avHoaHu-bx_DmBK1LzkTRVBU_RWtCiCh41dBzdJHS2yx5SfgKrSgrG0HpGo3bECP0KrvgsYb8CeCx6Z13RvU4QhqDT4BzwM5niD1M785jivMBohqPWPkOpyll5Tx0eIyhm8xPVrA4T0OI2IOJIbmErTI5xEt0ZlWf4GqZG_T6cP-y3RX758en7d2-OFApcyFopUVNVWU1J5xrqjgDYSuumVUVMZpJIwQREkrWaCBSzFp-b6m67CywDbr9zZ1v-pgg5XZwyUDfKw9hSm0ja0kYFf-CJa9rKng9g9cLOOkBunaMblDx2C5dzv7N4qs0l2ej8salP6yWJZ1_w74AF1F_mw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15662856</pqid></control><display><type>article</type><title>Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><creator>BLAY, J.-Y ; FAVROT, M. C ; NEGRIER, S ; COMBARET, V ; SALEM CHOUAIB ; MERCATELLO, A ; KAEMMERLEN, P ; FRANKS, C. R ; PHILIP, T</creator><creatorcontrib>BLAY, J.-Y ; FAVROT, M. C ; NEGRIER, S ; COMBARET, V ; SALEM CHOUAIB ; MERCATELLO, A ; KAEMMERLEN, P ; FRANKS, C. R ; PHILIP, T</creatorcontrib><description>Twenty-five previously untreated patients with metastatic renal cell carcinoma were treated with 5-day cycles of continuous infusion of interleukin 2 (IL2) and lymphokine-activated killer cell reinfusion. Five achieved a partial response. Three patients were found to have detectable tumor necrosis factor (TNF) in serum before initiation of therapy. On the fifth day of therapy, 24 patients had circulating TNF with immunoradiometric assay whereas 13 had detectable biological activity. Two days after the end of IL2 therapy, TNF concentration (immunoradiometric assay) decreased in most cases but was still detectable in 17 patients. Thirteen patients had still circulating TNF bioactivity. Although there was no significant difference between TNF levels observed on the fifth day of therapy in the responder and nonresponder groups, 48 h after the end of IL2 infusion, both the TNF concentration and the biological activity were significantly higher in the group of responder patients. This result suggests that the clinical response to IL2 therapy in patients with metastatic renal cell carcinoma is correlated to a sustained production of TNF after the end of IL2 infusion.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 2317822</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Animals ; Antineoplastic agents ; Biological and medical sciences ; Biomarkers - blood ; Carcinoma, Renal Cell - therapy ; Cell Survival - drug effects ; Chemotherapy ; Humans ; Infusions, Intravenous ; Interleukin-2 - administration & dosage ; Interleukin-2 - therapeutic use ; Kidney Neoplasms - therapy ; Killer Cells, Lymphokine-Activated - immunology ; Killer Cells, Lymphokine-Activated - transplantation ; L Cells (Cell Line) - cytology ; L Cells (Cell Line) - drug effects ; Lymphocyte Activation ; Medical sciences ; Mice ; Pharmacology. Drug treatments ; Radioimmunoassay ; Tumor Necrosis Factor-alpha - biosynthesis ; Tumor Necrosis Factor-alpha - pharmacology</subject><ispartof>Cancer research (Chicago, Ill.), 1990-04, Vol.50 (8), p.2371-2374</ispartof><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6912153$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2317822$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BLAY, J.-Y</creatorcontrib><creatorcontrib>FAVROT, M. C</creatorcontrib><creatorcontrib>NEGRIER, S</creatorcontrib><creatorcontrib>COMBARET, V</creatorcontrib><creatorcontrib>SALEM CHOUAIB</creatorcontrib><creatorcontrib>MERCATELLO, A</creatorcontrib><creatorcontrib>KAEMMERLEN, P</creatorcontrib><creatorcontrib>FRANKS, C. R</creatorcontrib><creatorcontrib>PHILIP, T</creatorcontrib><title>Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Twenty-five previously untreated patients with metastatic renal cell carcinoma were treated with 5-day cycles of continuous infusion of interleukin 2 (IL2) and lymphokine-activated killer cell reinfusion. Five achieved a partial response. Three patients were found to have detectable tumor necrosis factor (TNF) in serum before initiation of therapy. On the fifth day of therapy, 24 patients had circulating TNF with immunoradiometric assay whereas 13 had detectable biological activity. Two days after the end of IL2 therapy, TNF concentration (immunoradiometric assay) decreased in most cases but was still detectable in 17 patients. Thirteen patients had still circulating TNF bioactivity. Although there was no significant difference between TNF levels observed on the fifth day of therapy in the responder and nonresponder groups, 48 h after the end of IL2 infusion, both the TNF concentration and the biological activity were significantly higher in the group of responder patients. This result suggests that the clinical response to IL2 therapy in patients with metastatic renal cell carcinoma is correlated to a sustained production of TNF after the end of IL2 infusion.</description><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Carcinoma, Renal Cell - therapy</subject><subject>Cell Survival - drug effects</subject><subject>Chemotherapy</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Interleukin-2 - administration & dosage</subject><subject>Interleukin-2 - therapeutic use</subject><subject>Kidney Neoplasms - therapy</subject><subject>Killer Cells, Lymphokine-Activated - immunology</subject><subject>Killer Cells, Lymphokine-Activated - transplantation</subject><subject>L Cells (Cell Line) - cytology</subject><subject>L Cells (Cell Line) - drug effects</subject><subject>Lymphocyte Activation</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Pharmacology. Drug treatments</subject><subject>Radioimmunoassay</subject><subject>Tumor Necrosis Factor-alpha - biosynthesis</subject><subject>Tumor Necrosis Factor-alpha - pharmacology</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUFLxDAQhYMo67r6E4QcxFshTZo2OcqirrDgRc8lSSdstE1qkiL7761avHoaHu-bx_DmBK1LzkTRVBU_RWtCiCh41dBzdJHS2yx5SfgKrSgrG0HpGo3bECP0KrvgsYb8CeCx6Z13RvU4QhqDT4BzwM5niD1M785jivMBohqPWPkOpyll5Tx0eIyhm8xPVrA4T0OI2IOJIbmErTI5xEt0ZlWf4GqZG_T6cP-y3RX758en7d2-OFApcyFopUVNVWU1J5xrqjgDYSuumVUVMZpJIwQREkrWaCBSzFp-b6m67CywDbr9zZ1v-pgg5XZwyUDfKw9hSm0ja0kYFf-CJa9rKng9g9cLOOkBunaMblDx2C5dzv7N4qs0l2ej8salP6yWJZ1_w74AF1F_mw</recordid><startdate>19900415</startdate><enddate>19900415</enddate><creator>BLAY, J.-Y</creator><creator>FAVROT, M. C</creator><creator>NEGRIER, S</creator><creator>COMBARET, V</creator><creator>SALEM CHOUAIB</creator><creator>MERCATELLO, A</creator><creator>KAEMMERLEN, P</creator><creator>FRANKS, C. R</creator><creator>PHILIP, T</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19900415</creationdate><title>Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor</title><author>BLAY, J.-Y ; FAVROT, M. C ; NEGRIER, S ; COMBARET, V ; SALEM CHOUAIB ; MERCATELLO, A ; KAEMMERLEN, P ; FRANKS, C. R ; PHILIP, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h299t-824b862a4fb5055b2a53e8f45b3fa40cb39c88089e137be0989c89824ba61dfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Carcinoma, Renal Cell - therapy</topic><topic>Cell Survival - drug effects</topic><topic>Chemotherapy</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Interleukin-2 - administration & dosage</topic><topic>Interleukin-2 - therapeutic use</topic><topic>Kidney Neoplasms - therapy</topic><topic>Killer Cells, Lymphokine-Activated - immunology</topic><topic>Killer Cells, Lymphokine-Activated - transplantation</topic><topic>L Cells (Cell Line) - cytology</topic><topic>L Cells (Cell Line) - drug effects</topic><topic>Lymphocyte Activation</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Pharmacology. Drug treatments</topic><topic>Radioimmunoassay</topic><topic>Tumor Necrosis Factor-alpha - biosynthesis</topic><topic>Tumor Necrosis Factor-alpha - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BLAY, J.-Y</creatorcontrib><creatorcontrib>FAVROT, M. C</creatorcontrib><creatorcontrib>NEGRIER, S</creatorcontrib><creatorcontrib>COMBARET, V</creatorcontrib><creatorcontrib>SALEM CHOUAIB</creatorcontrib><creatorcontrib>MERCATELLO, A</creatorcontrib><creatorcontrib>KAEMMERLEN, P</creatorcontrib><creatorcontrib>FRANKS, C. R</creatorcontrib><creatorcontrib>PHILIP, T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BLAY, J.-Y</au><au>FAVROT, M. C</au><au>NEGRIER, S</au><au>COMBARET, V</au><au>SALEM CHOUAIB</au><au>MERCATELLO, A</au><au>KAEMMERLEN, P</au><au>FRANKS, C. R</au><au>PHILIP, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1990-04-15</date><risdate>1990</risdate><volume>50</volume><issue>8</issue><spage>2371</spage><epage>2374</epage><pages>2371-2374</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>Twenty-five previously untreated patients with metastatic renal cell carcinoma were treated with 5-day cycles of continuous infusion of interleukin 2 (IL2) and lymphokine-activated killer cell reinfusion. Five achieved a partial response. Three patients were found to have detectable tumor necrosis factor (TNF) in serum before initiation of therapy. On the fifth day of therapy, 24 patients had circulating TNF with immunoradiometric assay whereas 13 had detectable biological activity. Two days after the end of IL2 therapy, TNF concentration (immunoradiometric assay) decreased in most cases but was still detectable in 17 patients. Thirteen patients had still circulating TNF bioactivity. Although there was no significant difference between TNF levels observed on the fifth day of therapy in the responder and nonresponder groups, 48 h after the end of IL2 infusion, both the TNF concentration and the biological activity were significantly higher in the group of responder patients. This result suggests that the clinical response to IL2 therapy in patients with metastatic renal cell carcinoma is correlated to a sustained production of TNF after the end of IL2 infusion.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>2317822</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-5472 |
| ispartof | Cancer research (Chicago, Ill.), 1990-04, Vol.50 (8), p.2371-2374 |
| issn | 0008-5472 1538-7445 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79690328 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research |
| subjects | Animals Antineoplastic agents Biological and medical sciences Biomarkers - blood Carcinoma, Renal Cell - therapy Cell Survival - drug effects Chemotherapy Humans Infusions, Intravenous Interleukin-2 - administration & dosage Interleukin-2 - therapeutic use Kidney Neoplasms - therapy Killer Cells, Lymphokine-Activated - immunology Killer Cells, Lymphokine-Activated - transplantation L Cells (Cell Line) - cytology L Cells (Cell Line) - drug effects Lymphocyte Activation Medical sciences Mice Pharmacology. Drug treatments Radioimmunoassay Tumor Necrosis Factor-alpha - biosynthesis Tumor Necrosis Factor-alpha - pharmacology |
| title | Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T23%3A47%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlation%20between%20clinical%20response%20to%20interleukin%202%20therapy%20and%20sustained%20production%20of%20tumor%20necrosis%20factor&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=BLAY,%20J.-Y&rft.date=1990-04-15&rft.volume=50&rft.issue=8&rft.spage=2371&rft.epage=2374&rft.pages=2371-2374&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E79690328%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15662856&rft_id=info:pmid/2317822&rfr_iscdi=true |